Synergistic effect of ginsenoside Rg3 with verapamil on the modulation of multidrug resistance in human acute myeloid leukemia cells

Oncology Letters

Volumn 7, Issue 4, 2014, Pages 1265-1269

  Kim, Sung Su ^a   Seong, Sin ^a   Kim, Sung Young ^b  

^a Kyung Hee University   (South Korea)

^b Konkuk University School of Medicine   (South Korea)

Author keywords

Acute myeloid leukemia; Ginsenoside; Multidrug resistance; Rg3; Verapamil

Indexed keywords

BROXURIDINE; DOXORUBICIN; GINSENOSIDE RG 3; VERAPAMIL; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CELL VIABILITY; DRUG ACTIVITY; HUMAN; HUMAN CELL; IC 50; ISOBOLOGRAM ANALYSIS; MULTIDRUG RESISTANCE; OPTICAL DENSITY; STATISTICAL ANALYSIS;

EID: 84896734412     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.1826     Document Type: Article

References (25)

1. Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C and Gottesman MM: Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5: 219-234, 2006.
2. Liscovitch M and Lavie Y: Cancer multidrug resistance: a review of recent drug discovery research. IDrugs 5: 349-355, 2002.
3. Kitagawa I, Yoshikawa M, Yoshihara M, Hayashi T and Taniyama T: Chemical studies of crude drugs (1). Constituents of Ginseng radix rubra. Yakugaku Zasshi 103: 612-622, 1983 (In Japanese).
4. Kim SW, Kwon HY, Chi DW, et al: Reversal of P-glycoprotein-mediated multidrug resistance by ginsenoside Rg(3). Biochem Pharmacol 65: 75-82, 2003.
5. Molnár J, Szabó D, Pusztai R, et al: Membrane associated antitumor effects of crocine-, ginsenoside-and cannabinoid derivates. Anticancer Res 20: 861-867, 2000.
6. Tachikawa E, Kudo K, Nunokawa M, Kashimoto T, Takahashi E and Kitagawa S: Characterization of ginseng saponin ginsenoside-Rg(3) inhibition of catecholamine secretion in bovine adrenal chromaffin cells. Biochem Pharmacol 62: 943-951, 2001.
7. Jin J, Shahi S, Kang HK, van Veen HW and Fan TP: Metabolites of ginsenosides as novel BCRP inhibitors. Biochem Biophys Res Commun 345: 1308-1314, 2006.
8. Marquardt D, McCrone S and Center MS: Mechanisms of multidrug resistance in HL60 cells: detection of resistance-associated proteins with antibodies against synthetic peptides that correspond to the deduced sequence of P-glycoprotein. Cancer Res 50: 1426-1430, 1990.
9. Steel GG and Peckham MJ: Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 5: 85-91, 1979.
10. Kano Y, Ohnuma T, Okano T and Holland JF: Effects of vincristine in combination with methotrexate and other antitumor agents in human acute lymphoblastic leukemia cells in culture. Cancer Res 48: 351-356, 1988.
11. Kano Y, Suzuki K, Akutsu M, et al: Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer 50: 604-610, 1992.
12. Steel GG: Terminology in the description of drug-radiation interactions. Int J Radiat Oncol Biol Phys 5: 1145-1150, 1979.
13. Ford JM and Hait WN: Pharmacologic circumvention of multidrug resistance. Cytotechnology 12: 171-212, 1993.
14. Tsuruo T, Iida H, Tsukagoshi S and Sakurai Y: Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41: 1967-1972, 1981.
15. Belpomme D, Gauthier S, Pujade-Lauraine E, et al: Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma. Annal Oncol: 11: 1471-1476, 2000.
16. Hu XF, Martin TJ, Bell DR, de Luise M and Zalcberg JR: Combined use of cyclosporin A and verapamil in modulating multidrug resistance in human leukemia cell lines. Cancer Res 50: 2953-2957, 1990.
17. Ford JM, Bruggemann EP, Pastan I, Gottesman MM and Hait WN: Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines. Cancer Res 50: 1748-1756, 1990.
18. Van de Vrie W, Jonker AM, Marquet RL and Eggermont AM: The chemosensitizer cyclosporin A enhances the toxic side-effects of doxorubicin in the rat. J Cancer Res Clin Oncol 120: 533-538, 1994.
19. Lü JM, Yao Q and Chen C: Ginseng compounds: an update on their molecular mechanisms and medical applications. Curr Vasc Pharmacol 7: 293-302, 2009.
20. Park JD, Kim DS, Kwan HY, Son SK, Lee YH, Beak NI, et al: Effects of ginseng saponin on modulation of multidrug resistance. Arch Pharm Res 19: 213-218, 1996.
21. Jia WW, Bu X, Philips D, et al: Rh2, a compound extracted from ginseng, hypersensitizes multidrug-resistant tumor cells to chemotherapy. Can J Physiol Pharmacol 82: 431-437, 2004.
22. Helms S: Cancer prevention and therapeutics: Panax ginseng. Altern Med Rev 9: 259-274, 2004.
23. Yuan HD, Quan HY, Zhang Y, Kim SH and Chung SH: 20(S)-Ginsenoside Rg3-induced apoptosis in HT-29 colon cancer cells is associated with AMPK signaling pathway. Mol Med Rep 3: 825-831, 2010.
24. Jian J, Hu ZF and Huang Y: Effect of ginsenoside Rg3 on Pim-3 and Bad proteins in human pancreatic cancer cell line PANC-1. Ai Zheng 28: 461-465, 2009 (In Chinese).
25. Wang BS, Zhang LS, Song DM, Zhang JH and Liu YM: Effect of gensenoside Rg3 on apoptosis of Hep-2 and expression of HIF-1alpha in human laryngeal cancer cell line under anoxic conditions. Zhong Yao Cai 32: 102-106, 2009 (In Chinese).